140 related articles for article (PubMed ID: 35729536)
21. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Hunt BG; Wicker CA; Bourn JR; Lower EE; Takiar V; Waltz SE
Breast Cancer Res Treat; 2020 Jun; 181(3):529-540. PubMed ID: 32342233
[TBL] [Abstract][Full Text] [Related]
22. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
[TBL] [Abstract][Full Text] [Related]
24. Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
Wu J; Mamidi TKK; Zhang L; Hicks C
Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30909550
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
26. Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
Zhang Y; Zhang L; Li R; Chang DW; Ye Y; Minna JD; Roth JA; Han B; Wu X
Ann Oncol; 2017 Jul; 28(7):1625-1630. PubMed ID: 28383694
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
Fan C; Liu N; Fan S; Yang Z; Ye N; Wang K
Oncol Rep; 2019 Oct; 42(4):1580-1588. PubMed ID: 31364747
[TBL] [Abstract][Full Text] [Related]
28. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
29. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.
Cao X; Zhou Y; Mao F; Lin Y; Zhou X; Sun Q
Int Immunopharmacol; 2022 May; 106():108561. PubMed ID: 35151947
[TBL] [Abstract][Full Text] [Related]
31. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
[TBL] [Abstract][Full Text] [Related]
32. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.
Zuo WJ; He M; Zheng H; Liu Y; Liu XY; Jiang YZ; Wang ZH; Lu RQ; Shao ZM
Gland Surg; 2021 Apr; 10(4):1300-1314. PubMed ID: 33968682
[TBL] [Abstract][Full Text] [Related]
33. Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients.
Heng J; Guo X; Wu W; Wang Y; Li G; Chen M; Peng L; Wang S; Dai L; Tang L; Wang J
PLoS One; 2017; 12(3):e0174022. PubMed ID: 28301567
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
35. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
36. Overexpression and mutation of
Wan F; Zhou J; Chen X; Wang Y; Chen F; Chen Y
Transl Cancer Res; 2019 Jun; 8(3):779-787. PubMed ID: 35116816
[TBL] [Abstract][Full Text] [Related]
37. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
38. CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study.
Huang F; Peng Y; Ye Q; Chen J; Li Y; Liu S; Xu Y; Huang L
World J Surg Oncol; 2020 Oct; 18(1):274. PubMed ID: 33099318
[TBL] [Abstract][Full Text] [Related]
39. Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.
Kawaguchi T; Yan L; Qi Q; Peng X; Edge SB; Young J; Yao S; Liu S; Otsuji E; Takabe K
Ann Surg Oncol; 2018 Dec; 25(13):4037-4046. PubMed ID: 30311168
[TBL] [Abstract][Full Text] [Related]
40. Binning somatic mutations based on biological knowledge for predicting survival: an application in renal cell carcinoma.
Kim D; Li R; Dudek SM; Wallace JR; Ritchie MD
Pac Symp Biocomput; 2015; ():96-107. PubMed ID: 25592572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
